Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Richmond, Virginia 23298


Purpose:

RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue. PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.


Study summary:

OBJECTIVES: - Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors. - Assess the toxicities of this treatment regimen in these patients. - Determine tumor response and cause of death in these patients treated with this regimen. OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.


Criteria:

DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed malignancy - Extracranial recurrent or metastatic disease or primary tumor not predicted to be controlled with standard radiotherapy - Incurable with any standard therapy - No tumors involving critical structures (e.g., mucosal surfaces (bowel or bladder) or heart) - Tumor visible by CT scan PATIENT CHARACTERISTICS: Age: - Not specified Performance status: - Karnofsky 60-100% Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Bilirubin less than 2.0 times upper limit of normal (ULN) - AST and ALT less than 5 times ULN Renal: - Creatinine less than 2.0 mg/dL Pulmonary: - FEV1 greater than 0.75 L Other: - No unsuitable size or geometric proportion that would preclude stereotactic immobilization - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 14 days since prior anticancer biologic therapy and recovered Chemotherapy: - At least 14 days since prior anticancer chemotherapy and recovered Endocrine therapy: - At least 14 days since prior anticancer endocrine therapy and recovered Radiotherapy: - See Disease Characteristics - At least 14 days since prior anticancer radiotherapy and recovered Surgery: - Not specified


NCT ID:

NCT00006456


Primary Contact:

Study Chair
Danny Y. Song, MD
Massey Cancer Center


Backup Contact:

N/A


Location Contact:

Richmond, Virginia 23298
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.